Vanqua Bio Joins Scientific Discussions
Located in Chicago, Vanqua Bio is a pioneering biopharmaceutical company that is making impressive strides in tackling neurodegenerative diseases. With a commitment to cutting-edge research and innovative strategies, the company recently revealed its plans to participate in several important scientific conferences, where it will highlight its advancements in medicine.
Upcoming Conference Engagements
Vanqua Bio will take part in the Grand Challenges in Parkinson's Disease Symposium on September 23-24. This distinguished event will take place in Grand Rapids, bringing together leading experts to address urgent topics within the field. A poster presentation will focus on a validated glucocerebrosidase activity assay, which evaluates the in-vivo target engagement of allosteric GCase activators.
Poster Presentation Details
Session Date: Monday, September 23
Time: 12:30 p.m. - 2:30 p.m. ET
Presenter: Daniel Ysselstein, Ph.D., Vice President of Biology at Vanqua Bio.
International Congress on Parkinson's Disease and Movement Disorders
After the symposium, Vanqua Bio will also present at the International Congress of Parkinson's Disease and Movement Disorders, taking place from September 27 to October 1 in Philadelphia. This congress is an essential venue for sharing crucial advancements related to movement disorders, offering thorough reviews of the latest research in this domain.
Collaborative Research Presentation
At this event, Vanqua Bio will work alongside the Centre for Human Drug Research (CHDR) and Leiden University Medical Centre (LUMC). Their focus will be on the variability of ?-glucocerebrosidase activity in healthy volunteers versus patients with a GBA1 mutation. This presentation is set to be a vital examination of how these factors influence the diagnosis and treatment of Parkinson's disease.
About Vanqua Bio
Founded in 2019, Vanqua Bio stands at the forefront of biopharmaceutical innovation. The company utilizes a distinctive technology platform that combines human genetics and patient-derived neuronal cells to discover new pathways related to lysosomal dysfunction and the inappropriate activation of the innate immune system. Initially concentrating on glucocerebrosidase (GCase), the company's goal is to create transformative therapies for Parkinson's disease while also addressing neuroinflammation-related conditions, including Alzheimer’s disease.
Research and Development Objectives
Vanqua Bio is dedicated to converting its scientific breakthroughs into practical clinical solutions, potentially revolutionizing patient care with groundbreaking treatments that directly tackle the underlying causes of neurodegeneration.
Contact for Media Inquiries
If you're interested in media relations or need more information, please reach out to Alyssa Paldo at FINN Partners. She’s available to assist with any inquiries related to Vanqua Bio’s initiatives and research efforts.
Frequently Asked Questions
What is Vanqua Bio’s main area of focus?
Vanqua Bio is dedicated to developing advanced treatments for neurodegenerative diseases, specifically targeting glucocerebrosidase activity.
When and where will Vanqua Bio showcase its research?
Vanqua Bio will present at the Grand Challenges in Parkinson's Disease Symposium on September 23-24, followed by the International Congress of Parkinson's Disease and Movement Disorders from September 27 to October 1.
Who will present at the Grand Challenges in Parkinson's Disease Symposium?
Dr. Daniel Ysselstein, who serves as Vice President of Biology, will be the presenter at the symposium.
What research topics will be discussed during the presentations?
The presentations will explore glucocerebrosidase activity assays and the variability of biomarkers in both patients and healthy individuals.
How can I get in touch with Vanqua Bio for additional information?
For media inquiries, contact Alyssa Paldo at FINN Partners for further information regarding the company's research and initiatives.